DK1853588T3 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number: DK1853588T3
Authority: DK; Denmark
Prior art keywords: chemical compounds; novel compounds; cancer; formula; treatment
Prior art date: 2005-02-16

Application number

DK06709750T

Other languages

English (en)

Inventor

Michelle Lamb

Peter Array Mohr

Bin Array Wang

Tao Wang

Dingwei Yu

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-16

Filing date

2006-02-15

Publication date

2008-09-15

2006-02-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-09-15 Application granted granted Critical

2008-09-15 Publication of DK1853588T3 publication Critical patent/DK1853588T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

DK06709750T 2005-02-16 2006-02-15 Kemiske forbindelser DK1853588T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65357505P	2005-02-16	2005-02-16
US74213805P	2005-12-01	2005-12-01
PCT/GB2006/000513 WO2006087530A1 (en)	2005-02-16	2006-02-15	Chemical compounds

Publications (1)

Publication Number	Publication Date
DK1853588T3 true DK1853588T3 (da)	2008-09-15

Family

ID=36168456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06709750T DK1853588T3 (da)	2005-02-16	2006-02-15	Kemiske forbindelser

Country Status (21)

Country	Link
US (2)	US8129403B2 (da)
EP (1)	EP1853588B1 (da)
JP (1)	JP5001179B2 (da)
KR (1)	KR101362621B1 (da)
AT (1)	ATE398613T1 (da)
AU (1)	AU2006215386B2 (da)
BR (1)	BRPI0607455A2 (da)
CA (1)	CA2597813C (da)
CY (1)	CY1108275T1 (da)
DE (1)	DE602006001515D1 (da)
DK (1)	DK1853588T3 (da)
ES (1)	ES2308731T3 (da)
IL (1)	IL185063A (da)
MX (1)	MX2007009843A (da)
NO (1)	NO20073788L (da)
NZ (1)	NZ561525A (da)
PL (1)	PL1853588T3 (da)
PT (1)	PT1853588E (da)
RU (1)	RU2405780C2 (da)
SI (1)	SI1853588T1 (da)
WO (1)	WO2006087530A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
PT1846394E (pt) *	2005-02-04	2012-01-05	Astrazeneca Ab	Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es)	2005-02-16	2008-12-01	Astrazeneca Ab	Compuestos quimicos.
AU2006248780B2 (en) *	2005-05-16	2010-06-03	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) *	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7767685B2 (en) *	2006-06-29	2010-08-03	King Pharmaceuticals Research And Development, Inc.	Adenosine A2B receptor antagonists
ES2383370T3 (es)	2006-10-19	2012-06-20	Signal Pharmaceuticals Llc	Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
JP2010507581A (ja) *	2006-10-20	2010-03-11	ナームローゼ・フエンノートチヤツプ・オルガノン	ＰＫＣ−θ阻害薬としてのプリン類
CN101679429A (zh) *	2007-04-18	2010-03-24	阿斯利康(瑞典)有限公司	5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
GB0725218D0 (en) *	2007-12-24	2008-02-06	Syngenta Ltd	Chemical compounds
AU2009259026B2 (en) *	2008-06-11	2012-10-04	Astrazeneca Ab	Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
KR20110071098A (ko) *	2008-09-30	2011-06-28	아스트라제네카 아베	복소환 ｊａｋ 키나제 억제제
PA8851101A1 (es)	2008-12-16	2010-07-27	Lilly Co Eli	Compuesto amino pirazol
JP2013508456A (ja)	2009-10-26	2013-03-07	シグナルファーマシューティカルズ，エルエルシー	ヘテロアリール化合物の合成方法および精製方法
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011133920A1 (en)	2010-04-23	2011-10-27	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) *	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2012097478A1 (en) *	2011-01-21	2012-07-26	Abbott Laboratories	Bicyclic carboxamide inhibitors of kinases
SG10201912850WA (en)	2011-10-19	2020-02-27	Signal Pharm Llc	Treatment Of Cancer With TOR Kinase Inhibitors
ES2694413T3 (es)	2011-12-02	2018-12-20	Signal Pharmaceuticals, Llc	Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
CA2864905A1 (en)	2012-02-24	2013-08-29	Signal Pharmaceuticals, Llc	Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
SG11201405761WA (en)	2012-03-16	2014-10-30	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
TWI585088B (zh)	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2013188184A1 (en)	2012-06-14	2013-12-19	Eli Lilly And Company	Inhibitor of jak1 and jak2
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en)	2013-01-16	2017-06-28	Signal Pharmaceuticals, LLC	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CN105026398B (zh) *	2013-03-05	2018-05-18	默克专利股份公司	用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
US9370515B2 (en)	2013-03-07	2016-06-21	Califia Bio, Inc.	Mixed lineage kinase inhibitors and method of treatments
AU2014254057A1 (en)	2013-04-17	2015-11-05	Signal Pharmaceuticals, Llc	Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX368286B (es)	2013-04-17	2019-09-27	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt)	2013-04-17	2022-12-20	Signal Pharmaceuticals, Llc	Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
ES2944478T3 (es)	2013-04-17	2023-06-21	Signal Pharm Llc	1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
SG11201508527VA (en)	2013-04-17	2015-11-27	Signal Pharm Llc	Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
KR102242505B1 (ko)	2013-04-17	2021-04-20	시그날 파마소티칼 엘엘씨	암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
NZ629411A (en)	2013-04-17	2017-06-30	Signal Pharm Llc	Treatment of cancer with dihydropyrazino-pyrazines
JP6401250B2 (ja)	2013-05-29	2018-10-10	シグナルファーマシューティカルズ，エルエルシー	７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TWI663159B (zh)	2013-12-10	2019-06-21	美商健臻公司	原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en)	2014-04-16	2017-08-01	Signal Pharmaceuticals, Llc	Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9512129B2 (en)	2014-04-16	2016-12-06	Signal Pharmaceuticals, Llc	Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9737535B2 (en)	2014-04-16	2017-08-22	Signal Pharmaceuticals, Llc	Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
AU2015289929A1 (en)	2014-07-14	2017-03-02	Signal Pharmaceuticals, Llc	Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MY195799A (en)	2014-12-18	2023-02-21	Genzyme Corp	Pharmaceutical Formulations of Tropomyosin-Related Kinase (TRK) Inhibitors
HUE049801T2 (hu)	2014-12-23	2020-10-28	Sma Therapeutics Inc	3,5-diaminopirazol kináz inhibitorok
EP3641772B1 (en)	2017-06-22	2023-08-02	Celgene Corporation	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1417402A (en)	1972-03-30	1975-12-10	Boots Co Ltd	Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de)	1974-05-29	1975-12-18	Bayer Ag	Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) *	1982-01-11	1984-11-27	Advanced Moisture Technology, Inc.	Apparatus and process for microwave moisture analysis
US5006116A (en)	1988-12-21	1991-04-09	Kimberly-Clark Corporation	Tampon with single layer powder bonded wrap
HU206337B (en)	1988-12-29	1992-10-28	Mitsui Petrochemical Ind	Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) *	1992-08-31	1999-04-13	Miguel A. Cacho	Automated fluid bed process
US5543520A (en)	1993-10-01	1996-08-06	Ciba-Geigy Corporation	Pyrimidine derivatives
WO1997009325A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US5866702A (en) *	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) *	1996-08-16	1998-05-19	Berlex Laboratories, Inc.	Purine derivatives and their use as anti-coagulants
DK0970369T3 (da) *	1997-03-27	2002-01-28	Glatt Gmbh	Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget .....
CA2321153A1 (en)	1998-02-17	1999-08-19	Timothy D. Cushing	Anti-viral pyrimidine derivatives
US6247246B1 (en) *	1998-05-27	2001-06-19	Denver Instrument Company	Microwave moisture analyzer: apparatus and method
AU5438299A (en)	1998-08-29	2000-03-21	Astrazeneca Ab	Pyrimidine compounds
WO2000014552A1 (en)	1998-09-03	2000-03-16	Malcam Ltd.	Moisture measurement device using microwaves
US6227041B1 (en)	1998-09-17	2001-05-08	Cem Corporation	Method and apparatus for measuring volatile content
AU762523C (en)	1998-11-10	2004-02-12	Janssen Pharmaceutica N.V.	HIV replication inhibiting pyrimidines
WO2000035455A1 (en)	1998-12-15	2000-06-22	Telik, Inc.	Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
DE19917785A1 (de)	1999-04-20	2000-10-26	Bayer Ag	2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it)	1999-05-26	2001-10-02	Sirs Societa Italiana Per La R	Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
EP1206265B1 (en) *	1999-06-30	2003-11-12	Merck & Co., Inc.	Src kinase inhibitor compounds
US6399780B1 (en) *	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
ATE309241T1 (de)	1999-09-10	2005-11-15	Merck & Co Inc	Tyrosin kinase inhibitoren
KR100820605B1 (ko)	1999-09-24	2008-04-08	얀센 파마슈티카 엔.브이.	항바이러스 조성물
US6455525B1 (en) *	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones
DE60043397D1 (de)	1999-12-28	2010-01-07	Pharmacopeia Inc	Cytokine, insbesondere tnf-alpha, hemmer
AU2001237041B9 (en)	2000-02-17	2005-07-28	Amgen Inc.	Kinase inhibitors
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US7034019B2 (en)	2000-05-08	2006-04-25	Janssen Pharmaceutica N.V.	Prodrugs of HIV replication inhibiting pyrimidines
CZ2003468A3 (cs)	2000-08-31	2004-05-12	Pfizeráproductsáinc	Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
US7071217B2 (en)	2000-09-01	2006-07-04	Smithkline Beecham Corporation	Substituted oxindole derivatives as tyrosine kinase inhibitors
EP1317446A1 (en)	2000-09-01	2003-06-11	Glaxo Group Limited	Oxindole derivatives
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en)	2000-09-15	2002-03-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en)	2000-12-21	2010-03-29	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2003011855A2 (en) *	2001-08-03	2003-02-13	Vertex Pharmaceuticals Incorporated	Pyrazole-derived kinase inhibitors and uses thereof
CA2456187A1 (en) *	2001-08-03	2003-02-13	Qing Tang	Pyrazole-derived kinase inhibitors and uses thereof
WO2003026666A1 (en)	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
JP2005508337A (ja)	2001-09-27	2005-03-31	スミスクラインビーチャムコーポレーション	化合物
US6747461B2 (en) *	2001-10-25	2004-06-08	Pioneer Hi-Bred International, Inc.	Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007052466A (ja)	2003-11-17	2007-03-01	Nec Corp	画像処理方法、画像処理システム、および画像処理プログラム
WO2005095400A1 (en)	2004-03-30	2005-10-13	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of jak and other protein kinases
JP2007533717A (ja) *	2004-04-21	2007-11-22	アストラゼネカアクチボラグ	化合物
US7528138B2 (en) *	2004-11-04	2009-05-05	Vertex Pharmaceuticals Incorporated	Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
DE102004053734B4 (de)	2004-11-06	2007-01-18	Sartorius Ag	Trocknungswaage
PT1846394E (pt)	2005-02-04	2012-01-05	Astrazeneca Ab	Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es)	2005-02-16	2008-12-01	Astrazeneca Ab	Compuestos quimicos.
AU2006215394B2 (en)	2005-02-16	2009-10-08	Astrazeneca Ab	Chemical compounds
WO2006115452A1 (en)	2005-04-27	2006-11-02	Astrazeneca Ab	Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006118231A1 (ja)	2005-04-28	2006-11-09	Mitsubishi Tanabe Pharma Corporation	シアノピリジン誘導体及びその医薬としての用途
JP2008540391A (ja) *	2005-05-05	2008-11-20	アストラゼネカアクチボラグ	ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
AU2006248780B2 (en)	2005-05-16	2010-06-03	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en)	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CN101316597B (zh) *	2005-11-03	2013-04-17	顶点医药品公司	用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) *	2006-06-30	2008-01-31	Astrazeneca Ab	Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
TW200823196A (en) *	2006-11-01	2008-06-01	Astrazeneca Ab	New use
TW200826937A (en) *	2006-11-01	2008-07-01	Astrazeneca Ab	New use

2006
- 2006-02-15 ES ES06709750T patent/ES2308731T3/es active Active
- 2006-02-15 BR BRPI0607455-3A patent/BRPI0607455A2/pt not_active IP Right Cessation
- 2006-02-15 NZ NZ561525A patent/NZ561525A/en not_active IP Right Cessation
- 2006-02-15 JP JP2007555688A patent/JP5001179B2/ja not_active Expired - Fee Related
- 2006-02-15 EP EP06709750A patent/EP1853588B1/en not_active Not-in-force
- 2006-02-15 KR KR1020077020887A patent/KR101362621B1/ko not_active Expired - Fee Related
- 2006-02-15 SI SI200630060T patent/SI1853588T1/sl unknown
- 2006-02-15 DK DK06709750T patent/DK1853588T3/da active
- 2006-02-15 RU RU2007134396/04A patent/RU2405780C2/ru not_active IP Right Cessation
- 2006-02-15 MX MX2007009843A patent/MX2007009843A/es active IP Right Grant
- 2006-02-15 WO PCT/GB2006/000513 patent/WO2006087530A1/en not_active Ceased
- 2006-02-15 AT AT06709750T patent/ATE398613T1/de active
- 2006-02-15 CA CA2597813A patent/CA2597813C/en not_active Expired - Fee Related
- 2006-02-15 DE DE602006001515T patent/DE602006001515D1/de active Active
- 2006-02-15 US US11/816,374 patent/US8129403B2/en not_active Expired - Fee Related
- 2006-02-15 PT PT06709750T patent/PT1853588E/pt unknown
- 2006-02-15 AU AU2006215386A patent/AU2006215386B2/en not_active Ceased
- 2006-02-15 PL PL06709750T patent/PL1853588T3/pl unknown
2007
- 2007-07-20 NO NO20073788A patent/NO20073788L/no not_active Application Discontinuation
- 2007-08-06 IL IL185063A patent/IL185063A/en not_active IP Right Cessation
2008
- 2008-08-21 CY CY20081100887T patent/CY1108275T1/el unknown
2012
- 2012-01-25 US US13/357,848 patent/US20120122892A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1108275T1 (el)	2014-02-12
RU2007134396A (ru)	2009-03-27
NZ561525A (en)	2010-11-26
KR101362621B1 (ko)	2014-02-13
PT1853588E (pt)	2008-08-25
JP2008530190A (ja)	2008-08-07
BRPI0607455A2 (pt)	2009-09-01
HK1114375A1 (en)	2008-10-31
JP5001179B2 (ja)	2012-08-15
SI1853588T1 (sl)	2008-10-31
MX2007009843A (es)	2007-08-23
KR20070103773A (ko)	2007-10-24
WO2006087530A1 (en)	2006-08-24
CA2597813C (en)	2014-04-22
NO20073788L (no)	2007-09-03
RU2405780C2 (ru)	2010-12-10
DE602006001515D1 (de)	2008-07-31
US20080176872A1 (en)	2008-07-24
EP1853588A1 (en)	2007-11-14
US20120122892A1 (en)	2012-05-17
US8129403B2 (en)	2012-03-06
IL185063A0 (en)	2007-12-03
ES2308731T3 (es)	2008-12-01
IL185063A (en)	2012-01-31
AU2006215386A1 (en)	2006-08-24
CA2597813A1 (en)	2006-08-24
EP1853588B1 (en)	2008-06-18
ATE398613T1 (de)	2008-07-15
PL1853588T3 (pl)	2008-11-28
AU2006215386B2 (en)	2009-06-11

Publication	Publication Date	Title
CY1110900T1 (el)	2015-06-10	Χημικες ενωσεις
CY1108275T1 (el)	2014-02-12	Χημικες ενωσεις
TW200716606A (en)	2007-05-01	Chemical compounds
TW200800963A (en)	2008-01-01	Chemical compounds
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201190235A1 (ru)	2012-05-30	Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200970156A1 (ru)	2009-08-28	Пиридизиноновые производные
EA201690265A3 (ru)	2016-10-31	Фармацевтические композиции, содержащие замещенные ациланилиды
CY1109911T1 (el)	2014-09-10	Πυρρολοβενζοδιαζεπινες
MY153915A (en)	2015-04-15	Organic compounds
EA200900023A1 (ru)	2009-06-30	Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
UA94129C2 (ru)	2011-04-11	Соединения для ингибирования митоза
EA200801997A1 (ru)	2009-04-28	Новые соединения
EA200801428A1 (ru)	2008-10-30	Производные пиридиазинона для лечения опухолей
EA200801362A1 (ru)	2009-02-27	Пиримидинил бензотиофеновые соединения
EA201000895A1 (ru)	2010-12-30	Композиции и способы для лечения лизосомных болезней
EA201170344A1 (ru)	2011-08-30	Азаиндольные ингибиторы iap
TW200738659A (en)	2007-10-16	Novel compounds
SG158091A1 (en)	2010-01-29	Imidazoazepinone compounds
TW200745122A (en)	2007-12-16	New compounds I
TW200616977A (en)	2006-06-01	Enantiomers of selected fused heterocyclics and uses thereof
ATE474574T1 (de)	2010-08-15	Imidazoazephinonverbindungen
TW200621260A (en)	2006-07-01	Selected fused heterocyclics and uses thereof
TW200745133A (en)	2007-12-16	New compounds II